Medplus Health Q4 FY26 profit up 25%, revenue +24%

Results snapshot: what changed in the March 2026 quarter

Medplus Health Services reported higher consolidated profit and sales for the quarter ended March 2026 (Q4FY26), reflecting stronger year-on-year operating performance. Consolidated net profit rose 24.62% to ₹63.98 crore, compared with ₹51.34 crore in the March 2025 quarter. Sales increased 23.50% to ₹1,864.39 crore from ₹1,509.61 crore in the year-ago period. The update was carried as a Capital Market news item and separately reported by Business Standard, which also highlighted the market reaction. Business Standard reported net profit at ₹63.97 crore versus ₹51.32 crore a year ago, broadly in line with the Capital Market figures. Revenue from operations was reported at ₹1,864.39 crore versus ₹1,509.6 crore year-on-year.

Profitability indicators: OPM, EBITDA, PBDT and PBT

Beyond headline profit, Medplus’ operating metrics showed incremental improvement. Operating profit margin (OPM) for the March 2026 quarter was reported at 9.07%, compared with 9.03% a year earlier. Profit before depreciation and tax (PBDT) increased to ₹156.29 crore from ₹125.33 crore, reflecting a 25% rise. Profit before tax (PBT) rose to ₹80.34 crore from ₹61.12 crore, up 31% year-on-year. Business Standard also reported EBITDA at ₹107.63 crore for the quarter, up from ₹80.33 crore. EBITDA margin was reported at 5.8% versus 5.3% in the year-ago quarter.

Full-year FY26 performance: profit up 46%, sales up 12%

For the year ended March 2026, Medplus Health Services reported a sharper rise in bottom line than in top line. Consolidated net profit rose 46.12% to ₹219.65 crore, compared with ₹150.32 crore in the year ended March 2025. Sales for the full year increased 12.33% to ₹6,892.47 crore from ₹6,136.05 crore. The reported annual OPM improved to 8.81% from 7.94% in the previous year. PBDT for the year came in at ₹558.20 crore versus ₹433.13 crore, up 29%. PBT rose 50% to ₹275.33 crore from ₹183.29 crore.

Stock market reaction: shares jump after Q4FY26 results

The Q4FY26 numbers triggered a sharp move in the stock during morning trade on May 21, 2026. Medplus Health Services shares zoomed 11.3% on the BSE and hit an intra-day high of ₹1,020.35 per share, as per Business Standard’s market report. At 10:01 AM, the share price had pared gains but was still up 8.67% at ₹995.55 per share. Over the same period, the BSE Sensex was up 0.37% at 75,596.27. The move was linked directly to the release of the March quarter results.

Company profile: retail pharmacy network and leadership

MedPlus Health Services is a pharmacy retail chain founded in 2006 by Gangadi Madhukar Reddy, who is the Founder, Managing Director, and Chief Executive Officer. The company has positioned itself around a trusted pharmacy proposition and technology-led supply chain efficiencies, as described in the Business Standard report. MedPlus operates over 5,000 stores across 800-plus cities in 10 states. The states listed were Tamil Nadu, Andhra Pradesh, Telangana, Karnataka, Odisha, West Bengal, Maharashtra, Kerala, Chhattisgarh, and Madhya Pradesh. The company employs over 28,000 permanent full-time employees across its operations. Its scale and geographic spread are central to how investors track execution and performance consistency.

Business mix: beyond stores to omni-channel and diagnostics

MedPlus’ business model extends beyond retail pharmacy, with presence in wholesale distribution and manufacturing and contract manufacturing of private label pharmaceutical, wellness, and FMCG products. The company also operates import and diagnostic centres, according to the report. It runs an omni-channel platform that links physical stores with digital ordering. Business Standard specifically noted medicine ordering via WhatsApp as part of its customer access model. For investors, the blend of store expansion and digital order flows is often watched alongside profitability and margins. The March quarter results and margin disclosures provide a clearer view of how operating leverage is tracking.

Prior updates investors had seen during FY26

Ahead of the March quarter release, investors had also seen periodic sales updates during FY26. A Business Standard results feed referenced consolidated December 2025 net sales of ₹1,806.12 crore, up 15.67% year-on-year (dated Feb 03, 2026). Other dated entries in the same feed included consolidated September 2025 net sales of ₹1,679.33 crore (dated Oct 31, 2025) and consolidated June 2025 net sales of ₹1,542.63 crore (dated Aug 12, 2025). These updates provide context that quarterly revenue has been reported in a similar ₹1,500 crore to ₹1,800 crore range through FY26, culminating in ₹1,864.39 crore in Q4FY26. The March 2026 quarter also showed a notable year-on-year profit increase versus the March 2025 base.

Key numbers table: Q4FY26 and FY26 vs year-ago

Why the update matters for investors

The March quarter update combined double-digit sales growth with faster profit growth, which is why it drew immediate attention in the market. The full-year FY26 numbers also showed a larger improvement in net profit than in sales, alongside a higher OPM versus FY25. For a retail-led model, these profitability markers help investors interpret whether growth is translating into better operating outcomes. The immediate stock move on May 21, 2026 reflected that focus, with the share price rising sharply after the results. At the same time, the reporting also underlines that different news sources may show minor rounding differences in the same quarter’s profit figure. What is consistent across the reports is the direction of change: profit and revenue both rose year-on-year.

Conclusion

Medplus Health Services reported consolidated Q4FY26 net profit of about ₹64 crore on sales of ₹1,864.39 crore, and also delivered higher full-year FY26 profit of ₹219.65 crore on sales of ₹6,892.47 crore. The stock responded with a sharp intraday rise on May 21, 2026 following the results release, as broader markets also traded higher.